A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Tyrosine kinase inhibitors (TKIs) targeting EGFR-mutant lung cancers promote a range of tumor regression responses to yield variable residual disease, a likely incubator for acquired resistance. Herein, rapid transcriptional responses induced by TKIs early in treatment that associate with the range...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Precis Oncol
Main Authors: Gurule, Natalia J., McCoach, Caroline E., Hinz, Trista K., Merrick, Daniel T., Van Bokhoven, Adriaan, Kim, Jihye, Patil, Tejas, Calhoun, Jacob, Nemenoff, Raphael A., Tan, Aik Choon, Doebele, Robert C., Heasley, Lynn E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8129124/
https://ncbi.nlm.nih.gov/pubmed/34001994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00181-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados